b'Controls | MRD ControlsLow Positive ControlsMinimal Residual Disease (MRD) testing is a valuable tool that allows investigators to study and monitor multiple myeloma (MM) , chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) and other hematologic diseases. Recent treatment advances have led to significantly increased clinical response and overall survival, but ultimately most subjects will relapse, driving the need for sensitive MRD monitoring. Sensitive and standardized testing such as NGS-based MRD may one day enable identification of those cases that will eventually relapse versus those who are potentially cured. In addition to the need for more sensitive tracking, it is clear that standardized methods are needed. Currently, MRD methods are highly subjective and recommendations are often based on consensus expert-shared knowledge and experience, not on a validated, objective method. Once specific rearrangements have been identified, LymphoTrack assays can be used with LymphoQuant and LymphoTrack Low Positive Controls to track these clonotype populations to a sensitivity as low as 10 -4 . LymphoTrack B-cell Low Positive Control LymphoTrack B-cell Low Positive Control can be used as a control for:Gene Rearrangements:IGH, IGK Chromosome Translocations:n/cMutations:n/c Catalog # Description4-088-0098 LymphoTrack B-cell Low Positive Control*LymphoTrack T-cell Low Positive Control LymphoTrack T-cell Low Positive Control can be used as a control for:Gene Rearrangements:TRB, TRG Chromosome Translocations:n/cMutations:n/c Catalog # Description4-088-0108 LymphoTrack T-cell Low Positive Control*Note: Same product listed on page 54 in MRD Solution section. *LymphoTrack Low Positive Controls are research use only (RUO), not for diagnostic procedures.140'